These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 11096224)
21. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184 [TBL] [Abstract][Full Text] [Related]
22. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Farlow MR Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366 [TBL] [Abstract][Full Text] [Related]
23. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Doraiswamy PM; Krishnan KR; Anand R; Sohn H; Danyluk J; Hartman RD; Veach J Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):705-12. PubMed ID: 12188103 [TBL] [Abstract][Full Text] [Related]
24. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Ritchie CW; Ames D; Clayton T; Lai R Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273 [TBL] [Abstract][Full Text] [Related]
25. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. Farlow MR; Lilly ML; BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242 [TBL] [Abstract][Full Text] [Related]
26. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Lamb HM; Goa KL Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418 [TBL] [Abstract][Full Text] [Related]
27. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485 [TBL] [Abstract][Full Text] [Related]
28. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097 [TBL] [Abstract][Full Text] [Related]
29. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369 [TBL] [Abstract][Full Text] [Related]
30. Rivastigmine in Alzheimer disease: efficacy over two years. Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280 [TBL] [Abstract][Full Text] [Related]
31. Electrocardiographic effects of rivastigmine. Morganroth J; Graham S; Hartman R; Anand R J Clin Pharmacol; 2002 May; 42(5):558-68. PubMed ID: 12017350 [TBL] [Abstract][Full Text] [Related]
32. High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease. Riepe MW J Clin Psychiatry; 2014 Mar; 75(3):288. PubMed ID: 24717382 [No Abstract] [Full Text] [Related]
33. Prediction of treatment response to rivastigmine in Alzheimer's dementia. Adler G; Brassen S; Chwalek K; Dieter B; Teufel M J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):292-4. PubMed ID: 14742608 [TBL] [Abstract][Full Text] [Related]
34. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]. Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268 [TBL] [Abstract][Full Text] [Related]
35. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related]
36. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291 [TBL] [Abstract][Full Text] [Related]
37. Rivastigmine (Exelon) for Alzheimer's disease. Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159 [No Abstract] [Full Text] [Related]
38. A review of rivastigmine: a reversible cholinesterase inhibitor. Williams BR; Nazarians A; Gill MA Clin Ther; 2003 Jun; 25(6):1634-53. PubMed ID: 12860489 [TBL] [Abstract][Full Text] [Related]
39. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. Schreiter Gasser U; Gasser T Fortschr Med Orig; 2001 Nov; 119(3-4):135-8. PubMed ID: 11789125 [TBL] [Abstract][Full Text] [Related]
40. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand. Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]